Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLALOC: Dual Therapy Switch in HIV
NCT06907056Phase 4Recruiting
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darunavir, cobicistat and lamivudine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoint: Proportion of subjects with HIV-1 RNA levels >50 copies/ml at 48 weeks. Started Nov 2023; status: recruiting.
02
Drugs
darunavircobicistatlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06907056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907056.